[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Missaoui N, Hmissa S, Trabelsi A, Frappart L, Mokni M, Korbi S: Cervix cancer in Tunisia: clinical and pathological study. Asian Pac J Cancer Prev; 2010;11(1):235-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervix cancer in Tunisia: clinical and pathological study.
  • INTRODUCTION: Uterine cervix cancer is the second most commonly diagnosed cancer among women worldwide.
  • DESIGN: In order to review the clinical and pathological features of cervix cancer in the center of Tunisia, a retrospective study was carried out on 410 cancer cases diagnosed in the Pathology Department, Farhet Hached University Hospital, Sousse, Tunisia (1993-2006).
  • Of the 410 patients, 90.5% had squamous cell carcinoma and 7.3% had adenocarcinoma.
  • One hundred thirty-eight patients were identified as being in early stages (0 and I) (33.6%) and 58.2% in advanced stages (II-IV).
  • Therapy consisted mainly in combination of radiotherapy and surgery in early stages (28.8%), and radiotherapy alone or associated with the chemotherapy in advanced stage (29.7%).
  • Surgery was the only treatment in 29.5% of cases.
  • CONCLUSION: A relatively large proportion of patients presented in stages II to IV, as compared to only 36% with early stages, emphasizing the need to reinforce the early detection of this cancer and its precursor lesions in the center of Tunisia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Retrospective Studies. Tunisia / epidemiology. Vaginal Smears. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593963.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


2. Paulsen T, Kjaerheim K, Kaern J, Norstein J, Onsrud M: [Examination, treatment and follow-up of ovarian cancer in Norway]. Tidsskr Nor Laegeforen; 2001 Sep 30;121(23):2696-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Examination, treatment and follow-up of ovarian cancer in Norway].
  • [Transliterated title] Utredning, behandling og etterkontroll av eggstokkreft i Norge.
  • BACKGROUND: In order to improve our knowledge about the medical examination, treatment and follow of cancer patients, suggestions have been put forward for a system for quality assurance of clinical data on cancer in Norway (Government White Paper 20: 1997).
  • MATERIAL AND METHODS: In spring 2000, a questionnaire was sent to 41 gynaecological departments with focus on ovarian cancer patients.
  • Four of the departments were regional cancer centres.
  • Standard gynaecological examination, vaginal ultrasonography and CA-125 determination were included in the diagnostic procedures in all departments.
  • Some differences were detected: Cytological examination of pleural effusions as part of the staging procedure was not performed by all hospitals.
  • Sixteen hospitals out of 37 operated on patients with FIGO stage I disease without performing lympadenectomy.
  • When operating on suspected FIGO stage II-IV disease, three out of 22 local hospitals never performed surgery of the intestines in order to achieve optimal tumour reduction.
  • All regional hospitals gave adjuvant chemotherapy to high-risk FIGO stage I patients.
  • Standard treatment in advanced stages was paclitaxel/carboplatinum.
  • Some hospitals participated in randomized trials on chemotherapy.
  • Third-line treatment depended on the patient's condition, earlier toxicity and response.
  • One regional centre preferred not to give any third-line chemotherapy.
  • Only a few hospitals recorded the patient's performance status (WHO or Karnofsky's grading table) during the treatment and follow-up.
  • Most of the gynaecological departments referred the patients to the regional hospital at the time of recurrence.
  • INTERPRETATION: There are differences between the hospitals in how they handle ovarian cancer patients.
  • One cannot, however, determine from this inquiry what kind of medical examination, treatment and follow-up is best.
  • An extended registration of ovarian cancer organised by the Cancer Registry of Norway will be started with the aim of providing reliable population-based data (the OVANOR project).
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Norway. Practice Patterns, Physicians'. Quality Assurance, Health Care. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699376.001).
  • [ISSN] 0029-2001
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Thomas L, Bataillard A, Brémond A, Fondrinier E, Fervers B, Achard JL, Lansac J, Bailly C, Hoffstetter S, Basuyau JP, d'Anjou J, Descamps P, Farsi F, Guastalla JP, Laffargue F, Rodier JF, Vincent P, Pigneux J: [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)]. Cancer Radiother; 2001 Apr;5(2):163-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)].
  • [Transliterated title] Standards, Options et Recommandations pour la radiothérapie des patientes atteintes de cancer de l'endomètre.
  • OBJECTIVES: To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the radiotherapy of carcinoma of the endometrium.
  • Once the guidelines were defined, the document was submitted for review to independent reviewers, and to the medical committees of the 20 French Cancer Centres.
  • RESULTS: The main recommendations for the radiotherapy of carcinoma of the endometrium are:.
  • 1) For grade 1 and 2 stage IA tumours, follow-up alone is standard as additional treatment.
  • For grade 1 and 2 stage IB tumours, vaginal brachytherapy or follow-up alone are options.
  • For grade 3, stage IB tumours and stage IC disease, there are two treatment options: external pelvic radiotherapy with a brachytherapy boost or vaginal brachytherapy.
  • 2) Treatment for stage II disease can be preoperative when stage II disease has been suggested by a positive endometrial curettage.
  • Postoperative vaginal brachytherapy is given for stage IIA tumours if the penetration of the myometrium is less than 50% or if the tumour is grade 1 or 2.
  • In the case of deep penetration, or higher grade disease, or for stage IIB external radiotherapy with brachytherapy boosting must be undertaken routinely.
  • 3) After surgery, for stage IIIA disease, either external pelvic radiotherapy or abdomino-pelvic radiotherapy is indicated, along with medical treatment in certain patients.
  • For stage IIIB tumours, postoperative external radiotherapy with brachytherapy (if possible) should be undertaken.
  • For stage IIIC tumours, standard treatment is external (pelvic or pelvic and para-aortic) radiotherapy followed or not by a brachytherapy boost.
  • 4) Standard treatment for inoperable stage I and II disease is external radiotherapy and brachytherapy.
  • For patients with inoperable stage III or IV disease, treatment is often symptomatic, combining external radiotherapy and medical treatment.
  • [MeSH-minor] Brachytherapy / adverse effects. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Cesium Radioisotopes / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Indium Radioisotopes / therapeutic use. Lymphatic Irradiation / adverse effects. Lymphatic Metastasis / radiotherapy. Neoplasm Staging. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary. Postoperative Period. Preoperative Care. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, High-Energy / adverse effects. Radium / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355582.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cesium Radioisotopes; 0 / Indium Radioisotopes; W90AYD6R3Q / Radium
  •  go-up   go-down


Advertisement
4. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1145-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
  • OBJECTIVE: To evaluate the risk of pelvic recurrence (PVR) in high-risk pathologic Stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone.
  • METHODS: Between 1992 and 1998, 43 high-risk endometrial cancer patients received adjuvant chemotherapy.
  • No patients received preoperative radiation therapy (RT).
  • Most patients had Stage III--IV disease (83.7%) or unfavorable histology tumors (74.4%).
  • All patients received 4-6 cycles of chemotherapy as the sole adjuvant therapy, consisting primarily of cisplatin and doxorubicin.
  • Recurrent disease sites were divided into pelvic (vaginal, nonvaginal) and extrapelvic (para-aortic, upper abdomen, liver, and extra-abdominal).
  • Of the 17 women who developed a PVR, 8 relapsed in the vagina, 3 in the nonvaginal pelvis, and 6 in both.
  • The 3-year vaginal and nonvaginal PVR rates were 37.8% and 26%, respectively.
  • The most significant factor correlated with vaginal PVR was CI (p = 0.0007).
  • Nine of the 29 relapsed patients (31%) developed PVR as their only (6) or first site (3) of recurrence.
  • Factors associated with a higher rate of PVR (as the first or only site) were CI and Stage I--II disease.
  • CONCLUSIONS: PVR is common in high-risk pathologic Stage I-IV endometrial cancer patients after adjuvant chemotherapy alone.
  • These results support the continued use of locoregional RT in patients undergoing adjuvant chemotherapy.
  • Further studies are needed to test the addition of chemotherapy to locoregional RT.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Endometrial Neoplasms / drug therapy. Pelvic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / prevention & control. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Adult. Aged. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Chicago / epidemiology. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma, Papillary / epidemiology. Cystadenocarcinoma, Papillary / prevention & control. Cystadenocarcinoma, Papillary / secondary. Cystadenocarcinoma, Papillary / therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Risk. Treatment Outcome. Vaginal Neoplasms / epidemiology. Vaginal Neoplasms / prevention & control. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483323.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Low JS, Wong EH, Tan HS, Yap SP, Chua EJ, Sethi VK, Soh LT, Low J, Tay EH, Chew SH: Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol; 2005 Apr;97(1):171-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
  • PURPOSE: To evaluate the efficacy and toxicity of adjuvant combination of sequential chemotherapy followed by radiotherapy in uterine papillary serous carcinoma (UPSC).
  • METHODS AND MATERIALS: From April 1994 to June 2003, 26 patients (median age 61.7 years, range 46.9-78.4) with UPSC were treated with a platinum-based chemoradiation protocol after definitive surgery.
  • 9 patients were assigned as stage I (35%), 4 were stage II (15%), 11 were stage III (42%), and 2 were stage IV (8%) according to the FIGO staging for gynecological cancers.
  • The adjuvant chemoradiation protocol consists of 4 cycles of platinum-based chemotherapy followed by pelvic irradiation and vaginal vault brachytherapy.
  • In selected stage I patients with no or minimal myometrial invasion, only vault brachytherapy was given after adjuvant chemotherapy.
  • 12 out of these 14 patients were FIGO stage I/II.
  • None of the patients developed local vault recurrence.
  • The treatment was well tolerated, only 1 patient developed congestive cardiac failure from the chemotherapy and 6 patients had grade 2 peripheral neuropathy on follow-up.
  • CONCLUSION: In our series of UPSC patients treated with adjuvant chemotherapy followed by radiotherapy, local control can be achieved in a majority of patients.
  • Further investigations into finding a more effective systemic therapy are required if improvement in outcome for this form of uterine cancer is to be achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / radiotherapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790454.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Mizuno K, Kidokoro K, Miyazaki K, Yoshida K, Nakagawa A, Mizuno M, Suzuki S, Kuno N, Furuhashi M, Ishizuka T, Ishikawa K: [Neoadjuvant chemotherapy with intra-arterial infusion in the treatment of advanced cervical cancer]. Gan To Kagaku Ryoho; 2005 Jun;32(6):815-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy with intra-arterial infusion in the treatment of advanced cervical cancer].
  • Neoadjuvant chemotherapy (NAC) with intra-arterial infusion was performed in the treatment for 53 patients with advanced cervical squamous cell carcinoma.
  • The response to therapy was observed in 45 of all patients (84.9%) clinically, and 36 of 42 patients (85.7%) pathologically.
  • Cancer cells disappeared in 11.9% of patients with cervical invasion, 69.2% with vaginal wall invasion and 39.4% with parametrium invasion after NAG.
  • Five-year survival rates were 100% in stage I, 71.5% in stage II, 52.2% in stage II and 0% in stage IV.
  • The group of patients without cancer in the parametrium after NAC showed a significantly better 5-year survival rate than the group with residual cancer in the parametrium.
  • According to the results, the elimination of cancer invasion to the parametrium by NAC is thought to be important for improvement of the prognosis in advanced cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hysterectomy. Lymph Node Excision. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Ifosfamide / administration & dosage. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Survival Rate. Vincristine / administration & dosage


7. Watari H, Mitamura T, Moriwaki M, Hosaka M, Ohba Y, Sudo S, Todo Y, Takeda M, Ebina Y, Sakuragi N: Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer; 2009 Dec;19(9):1585-90
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy.
  • We investigated the survival and the failure pattern of 288 patients with endometrial cancer treated with extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by cisplatin-based chemotherapy from 1982 to 2002.
  • The 5-year overall survival rates were 97.5% for stage I, 87.5% for stage II, 85.2% for stage III, and 12.5% for stage IV.
  • Notably, the 5-year survival rate was 76.5% for patients with stage IIIC disease.
  • Among patients with a low risk (n = 92) for recurrence who received no adjuvant chemotherapy, 2 (2.2%) showed recurrent disease.
  • Among those with intermediate (n = 98) and high (n = 98) risks for recurrence who received adjuvant chemotherapy, 9 (9.2%) and 20 (20.4%) showed recurrent disease, respectively.
  • The recurrence sites were described as follows: distant (n = 12), vaginal (n = 8), peritoneal (n = 7), pelvic (n = 2), and lymphatic (n = 2).
  • Cervical invasion and lymph node metastasis were predictors of vaginal failure.
  • For patients with stage I/II cancer, the architectural and nuclear grades were related to distant failure.
  • We conclude that we need to further test the efficacy of systemic adjuvant therapy using new chemotherapeutic regimens to prevent distant failure and to improve the survival of patients with endometrial cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery
  • [MeSH-minor] Aorta, Abdominal / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Gynecologic Surgical Procedures / methods. Humans. Lymph Node Excision. Pelvis / surgery. Recurrence. Retrospective Studies. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955942.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Sinha B, Stehman F, Schilder J, Clark L, Cardenes H: Indiana University experience in the management of vaginal cancer. Int J Gynecol Cancer; 2009 May;19(4):686-93
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indiana University experience in the management of vaginal cancer.
  • PURPOSE: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate.
  • MATERIALS AND METHODS: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities.
  • Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients).
  • RESULTS: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months).
  • The 5-year overall survival rates by stage were carcinoma in situ with microinvasion and stage I, 92%; stage II, 82%; and stages III and IVA, 20% (P = 0.0005).
  • The 5-year progression-free survival rates by stage were carcinoma in situ and stage I, 92%; stage II, 88%; and stages III and IVA, 30% (P = 0.00049).
  • Of the factors analyzed, only stage predicted for a statistically significant increased risk for recurrence (P = 2.23E-0.05).
  • CONCLUSIONS: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival.
  • Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated.
  • Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachytherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Vaginal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509572.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Morice P, Viala J, Pautier P, Lhommé C, Duvillard P, Castaigne D: Port-site metastasis after laparoscopic surgery for gynecologic cancer. A report of six cases. J Reprod Med; 2000 Oct;45(10):837-40
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-site metastasis after laparoscopic surgery for gynecologic cancer. A report of six cases.
  • BACKGROUND: Port-site metastasis after laparoscopic surgery for gynecologic cancer is a recognized entity.
  • CASES: Five patients underwent laparoscopic peritoneal biopsies for a stage III (n = 4) or IV (n = 1) ovarian cancer with moderate or poor differentiation.
  • The sixth patient underwent a laparoscopic lymphadenectomy for vaginal carcinoma with bulky metastatic pelvic lymph nodes.
  • If a malignant ovarian tumor is discovered during laparoscopy, the interval between initial surgery and complete cytoreductive surgery (with resection of laparoscopic ports) followed by chemotherapy should be as short as possible.
  • For patients with uterine cancer and bulky nodes, laparoscopic lymphadenectomy should be avoided to avoid trocar implantation metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Laparoscopy / adverse effects. Neoplasm Seeding. Ovarian Neoplasms / pathology. Skin Neoplasms / secondary. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11077634.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Kennedy AW, Austin JM Jr, Look KY, Munger CB: The Society of Gynecologic Oncologists Outcomes Task Force. Study of endometrical cancer: initial experiences. Gynecol Oncol; 2000 Dec;79(3):379-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Society of Gynecologic Oncologists Outcomes Task Force. Study of endometrical cancer: initial experiences.
  • OBJECTIVE: The aim of this study was to develop an outcomes measure, which incorporates patient reported information, for The Society of Gynecologic Oncologists (SGO) to establish benchmarks in the treatment of endometrial cancer and demonstrate quality to third parties.
  • METHODS: The Outcomes Task Force (OTF) developed an outcomes tool that included preoperative, intraoperative, and 120-day-postoperative assessments.
  • Seventy-four percent were FIGO stage I, 9% stage II, 11% stage III, and 5% stage IV.
  • Forty percent were FIGO grade 1, 35% grade 2, and 24% grade 3.
  • Seventy-seven percent of patients underwent total abdominal hysterectomy, 8% radical abdominal hysterectomy, 9% laparoscopic hysterectomy, and 1% vaginal hysterectomy.
  • 3 days and mean operative time was 119 min.
  • Postoperatively, 20% received radiation therapy and 13% received cytotoxic chemotherapy.
  • CONCLUSION: The SGO has developed a tool for assessing outcomes for the treatment of endometrial cancer that can be made available to the membership to assess and objectively demonstrate quality of care to third parties.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11104608.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol; 2005 Jun;97(3):924-7
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.
  • BACKGROUND: Intrauterine progesterone therapy potentially provides a simple alternative treatment for women with Stage I Grade I endometrial cancers who are at high risk for surgery.
  • The case histories of four women with early endometrial cancer primarily treated with levonorgestrel intrauterine system (Mirena) are reported and the literature reviewed.
  • CASES: Four women had Stage I grade 1 endometrial adenocarcinoma with positive progesterone receptor.
  • All were assessed to be in American Society of anaesthesiologists risk class IV.
  • One of three women who did not respond to treatment subsequently had a vaginal hysterectomy, which showed endometrial cancer with superficial myometrial invasion.
  • CONCLUSION: This report raises doubts about the effectiveness of intrauterine progesterone therapy as a definitive alternative for the treatment of early endometrial cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Levonorgestrel / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Routes. Female. Humans. Middle Aged. Uterus

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943993.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 13
  •  go-up   go-down


12. Ibrahim EM, Ezzat AA, Baloush A, Hussain ZH, Mohammed GH: Pregnancy-associated breast cancer: a case-control study in a young population with a high-fertility rate. Med Oncol; 2000 Nov;17(4):293-300
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy-associated breast cancer: a case-control study in a young population with a high-fertility rate.
  • Pregnancy-associated breast cancer (PABC) is not a rare event.
  • We intended to review the clinical features, therapy, and outcome of patients with PABC seen at a single institution over a five-year period and to compare those with that seen in a matched control group.
  • For each patient in Group I, three matched controls with breast cancer without pregnancy were identified (matched for age, stage, and year of diagnosis, Group II).
  • 3%, 31%, 40%, and 26% of patients had Stage I to IV, respectively.
  • A pattern that was similar to that seen in our breast cancer population.
  • Pregnancy was terminated in 34 patients (47%), while 38 (53%) had normal spontaneous vaginal delivery.
  • No patients in Group I had systemic chemotherapy during first trimester, while only 4 (6%) and 3 (4%) received adjuvant or neoadjuvant during second and third trimester, respectively.
  • Comparing overall survival (OS) between the two groups stage for stage also showed no significant difference.
  • Cox proportional hazard model identified advanced stage as the only independent adverse prognostic variable that influenced OS in Group I.
  • [MeSH-minor] Abortion, Induced. Adult. Age of Onset. Case-Control Studies. Disease-Free Survival. Female. Humans. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1958 Sep;107(3):271-83 [13580771.001]
  • [Cites] Am Surg. 1973 Feb;39(2):101-4 [4688837.001]
  • [Cites] Obstet Gynecol Clin North Am. 1998 Jun;25(2):353-63 [9629576.001]
  • [Cites] Teratology. 1976 Dec;14(3):355-7 [996782.001]
  • [Cites] Pharmacol Ther. 1997;74(2):207-20 [9336023.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):855-61 [10071276.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):869-72 [1991259.001]
  • [Cites] Am J Obstet Gynecol. 1963;85:312-21 [14041557.001]
  • [Cites] Arch Surg. 1985 Nov;120(11):1221-4 [4051725.001]
  • [Cites] Curr Probl Cancer. 1983 Mar;7(9):1-58 [6303698.001]
  • [Cites] Ann Saudi Med. 1997 Jan;17(1):53-65 [17377466.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):800-3 [6234984.001]
  • [Cites] Br J Surg. 1986 Aug;73(8):607-9 [3742168.001]
  • [Cites] South Med J. 1983 Sep;76(9):1088-90 [6612382.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):518-27 [8004627.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Surg Clin North Am. 1996 Apr;76(2):267-78 [8610263.001]
  • [Cites] Clin Obstet Gynecol. 1994 Dec;37(4):993-7 [7842568.001]
  • [Cites] Ann Saudi Med. 1997 Jan;17(1):10-5 [17377456.001]
  • (PMID = 11114708.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Bafna UD, Devi UM, Naik KA, Hazra S, Sushma N, Babu N: Carcinoma of the vulva: a retrospective review of 37 cases at a regional cancer centre in South India. J Obstet Gynaecol; 2004 Jun;24(4):403-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the vulva: a retrospective review of 37 cases at a regional cancer centre in South India.
  • A retrospective review of 37 cases of carcinoma of the vulva presenting between 1996 and 2000 has been carried out.
  • The surgical treatment consisted of wide excision in one case, radical vulvectomy (RV) in six cases, radical vulvectomy and bilateral groin node dissection (RV+BGND) in 25 cases and radical vulvectomy and unilateral groin node dissection in one case.
  • Nine of these 33 women also received adjuvant chemotherapy preoperatively in the hope of achieving better tumour-free surgical margins.
  • Thirteen of these 26 patients (50%) had inguinal node metastases (Stage III, four patients; Stage IV, nine patients).
  • All the patients with negative nodes were free of disease while three of four patients with Stage III and two of nine patients with Stage IV with nodal metastases remained free of disease.
  • The only patient with Stage III disease plus inguinal node metastases who recurred had multiple positive nodes with extracapsular spread.
  • It appears that although bilateral involvement of the inguinal lymph nodes carries a worse prognosis, unilateral involvement with or without vaginal involvement carries an excellent prognosis provided multiple nodes are not involved.
  • The role of neoadjuvant chemotherapy as compared to neoadjuvant radiotherapy, in locally advanced tumours, needs to be explored further.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. India / epidemiology. Lymphatic Metastasis. Medical Records. Medically Underserved Area. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Regional Medical Programs. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15203581.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Li SM, Zhang WH, Wu LY, Zhang R, Chen L: [Primary adenocarcinoma of vagina--attaching 24 cases clinical analysis]. Ai Zheng; 2002 Jan;21(1):83-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVES: The incidence of primary vaginal adenocarcinoma was lower and its treatment was difficult and its prognosis was worse.
  • This study was designed to explore the clinical characters, treatment, prognosis of primary vaginal adenocarcinoma in this paper as the incidence of primary vaginal adenocarcinoma was lower, its treatment was difficult and its prognosis was worse.
  • RESULTS: The main clinical symptoms were vaginal bleeding and discharge.
  • Five patients were classified as stage I, 10 patients were stage II, 5 patients were stage III, and 4 patients were stage IV.
  • Two patients were concurrently received chemotherapy and irradiation, Eight patients were received chemotherapy as the tumor was not control and recurrent or metastatic.
  • The survival mean time of patients with stage I and stage II was 60.3 months obviously much longer than 14.8 months of patients with stage III and stage IV, and they were significantly statistical difference (P < 0.01).
  • But the survival mean time of patients more than 40 years and less than or equal to 40 years was not significantly statistical difference.
  • Eight patients had local recurrence, which is the main reason of failure treatment.
  • CONCLUSIONS: Primary vaginal adenocarcinomas should mainly be adopted combined treatment depending on radiotherapy, but the prognosis was worse, the stage was the important factors affecting on the prognosis.
  • [MeSH-major] Adenocarcinoma / therapy. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500405.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-Madrid B, van Langendonckt A: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet; 2004 Oct 16-22;364(9443):1405-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.
  • BACKGROUND: The lifesaving treatment endured by cancer patients leads, in many women, to early menopause and subsequent infertility.
  • In clinical situations for which chemotherapy needs to be started, ovarian tissue cryopreservation looks to be a promising option to restore fertility.
  • In 1997, biopsy samples of ovarian cortex were taken from a woman with stage IV Hodgkin's lymphoma and cryopreserved before chemotherapy was initiated.
  • After her cancer treatment, the patient had premature ovarian failure.
  • METHODS: In 2003, after freeze-thawing, orthotopic autotransplantation of ovarian cortical tissue was done by laparoscopy.
  • FINDINGS: 5 months after reimplantation, basal body temperature, menstrual cycles, vaginal ultrasonography, and hormone concentrations indicated recovery of regular ovulatory cycles.
  • 11 months after reimplantation, human chorionic gonadotrophin concentrations and vaginal echography confirmed a viable intrauterine pregnancy, which has resulted in a livebirth.
  • INTERPRETATION: We have described a livebirth after orthotopic autotransplantation of cryopreserved ovarian tissue.
  • Our findings suggest that cryopreservation of ovarian tissue should be offered to all young women diagnosed with cancer.
  • [MeSH-major] Cryopreservation. Hodgkin Disease / drug therapy. Ovary / transplantation. Pregnancy. Tissue Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2012 Jul 14;380(9837):106; author reply 107; discussion 107-8 [22794237.001]
  • [CommentIn] Lancet. 2004 Oct 16-22;364(9443):1379-80 [15488198.001]
  • [CommentIn] Lancet. 2004 Dec 11-17;364(9451):2093-4 [15589301.001]
  • [CommentIn] Lancet. 2004 Dec 11-17;364(9451):2093 [15589302.001]
  • [CommentIn] Lancet. 2004 Dec 11-17;364(9451):2091-2; author reply 2092-3 [15589298.001]
  • [ErratumIn] Lancet. 2004 Dec 4;364(9450):2020
  • (PMID = 15488215.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Singhal P, Odunsi K, Rodabaugh K, Driscoll D, Lele S: Primary fallopian tube carcinoma: a retrospective clinicopathologic study. Eur J Gynaecol Oncol; 2006;27(1):16-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma: a retrospective clinicopathologic study.
  • INTRODUCTION: Primary fallopian tube carcinoma is a rare tumor.
  • The aim of this study was to evaluate clinical characteristics and management of fallopian tube malignancies at a large tertiary care cancer institute.
  • RESULTS: Thirty-five patients had histology consistent with fallopian tube carcinoma.
  • The most common signs or symptoms were abnormal vaginal bleeding (29%) and abdominal/pelvic mass (26%).
  • Five patients (14%) were Stage I, seven patients (20%) Stage II, 17 patients (49%) Stage III and six patients (17%) Stage IV.
  • Thirty-two (91%) patients received adjuvant chemotherapy and 77% received platinum-based chemotherapy.
  • The 5-year survival rate was 64% for Stage I, 42% for Stage II, 32% for Stage III, and 17% for Stage IV.
  • More extensive research needs to be performed to have definitive etiologic, diagnostic and treatment guidelines.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Cause of Death. Fallopian Tube Neoplasms / mortality. Fallopian Tube Neoplasms / pathology. Second-Look Surgery / trends
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Combined Modality Therapy. Female. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550961.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. An JS, Wu LY, Li N, Li B, Yu GZ, Liu LY: [Clinical analysis of 42 cases of primary malignant melanoma in female genital tract]. Zhonghua Fu Chan Ke Za Zhi; 2007 May;42(5):320-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the clinical characteristics, diagnosis, treatment and prognosis of primary malignant melanoma in female genital tract.
  • The 2-year cumulative overall survival rates for the patients of early stage [International Federation of Gynecology and Obstetrics (FIGO) stage I and II] and that of advanced stage (stage III and IV) were 77% and 34% respectively (P < 0.05).
  • The 2-year cumulative overall survival rates for the patients of stage I and stage II were 78% and 74% respectively (P = 0.303).
  • In the 40 patients who received surgery, univariate analysis showed that the adjuvant chemotherapy improved the recurrence-free survival and the overall survival significantly (P < 0.05), and the other factors including radical surgery, regional lymphadenectomy, biotherapy and radiotherapy did not affect prognosis (P > 0.05).
  • Compared with chemotherapy, biochemotherapy did not improve prognosis significantly (P > 0.05).
  • The FIGO staging system fails to predict the prognosis accurately.
  • Surgery plays an important role in treatment, while the adjuvant chemotherapy could improve survival effectively.
  • [MeSH-major] Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / therapy. Melanoma / diagnosis. Melanoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Lymph Node Excision. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. S100 Proteins / analysis. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / metabolism. Vaginal Neoplasms / therapy. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673044.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


18. Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK: [Clinical review of 97 patients with endometrial stromal sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):115-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review the survival outcomes in patients with endometrial stromal sarcoma (ESS) in Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, and to discuss prognostic factors and the role of post-operative adjuvant radiotherapy and chemotherapy.
  • The median follow-up time was 62 months (5 - 277 months).
  • Atypical vaginal bleeding (43%) and prolonged and increased menses (36%) were the main symptoms.
  • Cumulative survival curves were significantly different between LGESS and HGESS, and so did cumulative survival curves between stage I - II and stage III - IV (P < 0.05).
  • The median time-to-recurrence (TTR) was 27 months.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Sarcoma, Endometrial Stromal / pathology. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovariectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683750.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Li YF, Li MD, Wu QL, Liu FY, Li JD, Zou JL, Huang YW: [Clinical analysis of 57 patients with ovarian dysgerminoma]. Ai Zheng; 2002 Jan;21(1):79-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The data of 57 patients with pure Ovarian Dysgerminoma were analyzed retrospectively, who were admitted to Cancer Center, Sun Yat-sen University of Medical Sciences from January 1, 1964 to December 31, 2000.
  • RESULTS: The main clinical features were abdominal mass (56.1%), abdominal pain (21.1%), abdominal swelling(17.5%), vaginal bleeding(5.3%), genital tract abnormality (5.3%).
  • Twenty-six patients had stage Idiseases, 8 stage II, 9 stage III, 1 stage IV and 13 recurrent and persistent diseases.
  • The uterus was involved in 41.2% patients with stage II-III diseases.
  • Combined modality was given to 52 cases and single-method treatment 5 cases.
  • The overall 5-year and 10-year survival rate for stage I-IV was 80.1% and 70.0% respectively.
  • The 5-year survival rate for stage I was 100%, stage II 55.2%, stage III 55.6%, stage IV 0% and recurrent and persistent diseases 72.7%.
  • In the group of stage I, 12 patients received adnexectomy and 14 patients underwent hysterectomy and adnex removal, there was no significant difference between the 5-year and 10-year survival rate (all 100%) (P < 0.05).
  • Of 23 patients in stage I group to whom only chemotherapy were given after operation, 19 cases received 3 or more courses and were well being without recurrence; four patients received only one course and one of them recurred 21 months after operation.
  • In the group of stage II and III cases the 5-year survival rate was 86.7% for those whose chemotherapy courses were > or = 4 and 25.0% for patients who received less than 4 courses of chemotherapy (P < 0.05).
  • CONCLUSIONS: The prognosis of ovarian dysgerminoma is closely related to disease stage and modality of treatment.
  • [MeSH-major] Dysgerminoma / therapy. Ovarian Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500404.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE: Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol; 2004 Dec;95(3):469-73
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The coexistence of minimal uterine disease and extrauterine metastases is common in patients with uterine papillary serous carcinoma (UPSC).
  • The purpose of this study was to evaluate different therapeutic options in surgically staged patients.
  • RESULTS: Twenty-three (45%) cases were International Federation of Gynecology and Obstetrics (FIGO) stage IA, seven (15%) were stage IIIA, one (2%) was stage IIIC, and nine (18%) stage IV.
  • Additionally, 11 of these 51 patients (21%) were diagnosed with two cancers: a stage IA UPSC and concomitant advanced stage serous cancer of the ovary, fallopian tube, or peritoneum.
  • Stage IA patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease) had no recurrences (n = 10) regardless of treatment.
  • There was a trend toward increased survival in stage IA patients with residual uterine disease who were treated with chemoradiation (concomitant vaginal brachytherapy and platinum-based chemotherapy).
  • All patients with advanced stage UPSC (stage IIIC or IV or two primary cancers) did poorly regardless of treatment.
  • CONCLUSION: Our findings suggest that stage IA patients with no residual uterine disease may be observed.
  • Stage IA patients with residual uterine disease may benefit from chemoradiation.
  • More effective treatment needs to be identified for advanced stage UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581948.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


21. Nguyen NP, Sallah S, Karlsson U, Vos P, Ludin A, Semer D, Tait D, Salehpour M, Jendrasiak G, Robiou C: Prognosis for papillary serous carcinoma of the endometrium after surgical staging. Int J Gynecol Cancer; 2001 Jul-Aug;11(4):305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis for papillary serous carcinoma of the endometrium after surgical staging.
  • BACKGROUND: To investigate the pattern of failure and the prognosis following pathological staging for uterine papillary serous carcinoma (UPSC).
  • Two patients with advanced disease received chemotherapy only.
  • Two patients with early-stage disease were followed without further treatment.
  • In addition, seven of these patients received vaginal cuff irradiation with low-dose-rate or high-dose-rate brachytherapy.
  • RESULTS: Seven patients (32%) developed distant metastases, three out of seven (42%) after WART.
  • Four out of seven patients who had distant metastases died from disease progression during subsequent chemotherapy.
  • All patients with distant metastases had locally advanced-stage disease at presentation (six stage III, one stage IV).
  • Four patients with pelvic recurrences developed concurrent (2) and subsequent (2) distant metastases.
  • No patient with early stage-disease (stage I and II) died from disease progression.
  • CONCLUSION: Pathological staging should be performed for all patients with UPSC to determine the prognosis as well as to tailor the treatment.
  • The role of abdominal irradiation in the treatment of UPSC is yet to be determined; however, such an approach may not be necessary for the control of disease for patients with early-stage (I and II) disease.
  • Patients with locally advanced-stage (stage III) disease are at risk of local regional failures and distant metastases despite WART.
  • Therefore, the benefit of WART for advanced-stage disease is also questionable.
  • Paclitaxel-based chemotherapy is currently being investigated in this setting.
  • [MeSH-major] Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. North Carolina. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520370.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Liao Q, Wang J, Han J: [Clinical and pathological analysis on 106 cases with uterine sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2001 Feb;36(2):104-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the clinical features and factors affecting the prognosis of uterine sarcoma with different histological types.
  • According to Union Internationale Contre le Cancer (UICC) staging, 70 cases were on stage I, 12 cases were on stage II, 19 cases belonged to stage III, and 5 cases belonged to stage IV. RESULTS:.
  • The patients usually manifested with abnormal vaginal bleeding (67.0%), palpable mass of lower abdomen (32.1%), vaginal discharge (27.4%), pain on lower abdomen (28.4%), symptoms of oppression (25.5%), and discomfort feeling (28.3%). (2) The rate of preoperative diagnosis was 65.9%, especially that of leiomyosarcoma was lowest (42.9%). (3) In treatment, 16.0% of patients was treated by hysterectomy; bilateral salpingo-oophorectomy and pelvic lymphadenectomy; 75.5% of them by hysterectomy and bilateral salpingo-oophorectomy; after operation, 74.5% of them were treated by chemotherapy, 11.3% by radiotherapy, 6.6% by additional progesterone. (4) The survival period of the patients was related to pathologic types and clinical stages and ages of the patients.
  • The prognosis of the patients with leiomyosarcoma younger earlier stage was better.
  • CONCLUSIONS: The clinical symptom of uterine sarcoma is nonspecific (mostly abnormal vaginal bleeding) and the prognosis is poor.
  • The prognosis of uterine sarcoma is related to pathologic types, clinical stage and ages of the patients.

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783345.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Schumer ST, Cannistra SA: Granulosa cell tumor of the ovary. J Clin Oncol; 2003 Mar 15;21(6):1180-9
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients may present with vaginal bleeding caused by endometrial hyperplasia or uterine cancer as a result of prolonged exposure to tumor-derived estrogen.
  • Surgery is required for definitive tissue diagnosis, staging, and tumor debulking.
  • In women of childbearing age, a more conservative unilateral salpingo-oophorectomy may be performed, assuming that careful staging reveals that the disease has not extended outside of the involved ovary and that a concomitant uterine cancer has been excluded.
  • Survival of patients with GCT is generally excellent because most patients present with early-stage disease, although certain high-risk patient groups may be identified.
  • Stage is the most important prognostic factor, with a higher risk of relapse being associated with stages II through IV disease.
  • In addition, patients with stage I disease associated with features such as large tumor size, high mitotic index, or tumor rupture may also be at higher risk in some series.
  • The value of postoperative adjuvant therapy for high-risk patients has not been investigated by prospective randomized trials, which are difficult to perform because of the rarity of this tumor.
  • Nonetheless, the use of adjuvant chemotherapy or radiation has sometimes been associated with prolonged disease-free survival in patients with high-risk features.
  • [MeSH-minor] Age Factors. Anti-Mullerian Hormone. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Climacteric. Estradiol / blood. Female. Growth Inhibitors / analysis. Humans. Incidence. Inhibins / blood. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Population Surveillance. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Survival Rate. Testicular Hormones / analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12637488.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Growth Inhibitors; 0 / Organoplatinum Compounds; 0 / Testicular Hormones; 4TI98Z838E / Estradiol; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone
  • [Number-of-references] 75
  •  go-up   go-down


24. Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, Keeney GL: The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol; 2010 Mar;116(3):419-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of multi-modal therapy on survival for uterine carcinosarcomas.
  • OBJECTIVES: To investigate treatment outcomes of patients with carcinosarcoma of the uterus and to identify parameters predictive of survival.
  • Secondary objectives included (a) the assessment of treatment failures as a function of histologic subtypes and (b) the impact of the new FIGO staging classification system.
  • Clinical, surgical and pathological data were reviewed and patients were classified according to the new 2009 FIGO staging system for endometrial carcinoma.
  • RESULTS: In the multivariate analyses for disease-specific survival (DSS) and disease-free survival (DFS), the only independent factors were FIGO stage, adjuvant chemotherapy after surgery and the presence of clear cell histology in the tumor.
  • The 5-year DSS for stages I-II, III and IV was 59%, 22% and 9%, respectively.
  • The administration of platin-based chemotherapy provided a significant benefit with regard to both DFS (OR=0.28; p=0.001) and DSS (OR=0.35; p=0.01).
  • While radiotherapy (RT) appeared to control vaginal failures in all stages, pelvic RT did not impact DSS.
  • CONCLUSIONS: This highly aggressive uterine malignancy warrants comprehensive surgical staging to assess tumor dissemination followed by systemic therapy in patients with both early and advanced stage disease.
  • [MeSH-major] Carcinosarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896181.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • Anderson Cancer Center in a 16-year period (1990 to 2005).
  • The most common presentation was abdominal/pelvic pain (6 cases), followed by ascites (2 cases), pelvic mass, vaginal bleeding, and abdominal bloating (1 case each).
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • According to the International Federation of Gynecology and Obstetrics staging system, 4 cases were stage I tumors, 3 cases were stage III tumors, and 4 cases were stage IV tumors.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • Four of 5 patients who died of disease had either stage III or IV tumors and 3 of 5 patients who are alive without evidence of disease have stage I tumors.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Sorbe B, Bohr L, Karlsson L, Bermark B: Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences. Int J Oncol; 2010 Feb;36(2):371-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences.
  • In a series of 131 primary cervical carcinomas in FIGO stages I-IV suitable for combined external pelvic and intraluminal cervical-vaginal brachytherapy predictive and prognostic factors were analyzed with regard to locoregional tumor control, recurrences and survival data.
  • Patients with prior surgery or patients treated with external beam therapy alone were excluded from this series.
  • Concomitant chemotherapy was given to 47 patients (36%).
  • The external beam therapy was given with a four-field technique (50-60 Gy) and brachytherapy with high dose-rate (Ir-192) using a ring applicator set.
  • The dose (18-30 Gy) was specified according to the rules in ICRU 38 (a minimum dose to the surface of the target volume).
  • A CT-based 3-D dose-planning system (TMS) was used for the external beam therapy and for the brachytherapy planning (PLATO).
  • One hundred and eight tumors were in FIGO stages I-II and 23 tumors in stages III-IV.
  • A lower FIGO stage, chemoradiotherapy, squamous cell histology, diploid DNA-profile, a higher brachytherapy dose, more brachytherapy fractions and a higher total combined irradiation dose were favorable factors with regard to the risk of tumor recurrences.
  • The overall survival rate was 50% and the cancer-specific survival rate 65%.
  • Chemoradiotherapy therapy versus radiotherapy alone and squamous cell carcinomas versus adenocarcinomas were associated with improved survival rates.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043071.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ: Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol; 2001 Aug;82(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of endometrial carcinoma patients with involvement of the uterine serosa.
  • OBJECTIVE: The goal of this work was to evaluate the outcome of endometrial carcinoma patients undergoing primary surgery who have serosal involvement (SI).
  • METHODS: Between 1980 and 1998, 562 women underwent primary surgery for endometrial cancer at the University of Chicago.
  • FIGO stages were IIIA (19), IIIB (1), IIIC (7), and IV (12).
  • Twenty-six patients received pelvic radiation therapy (RT) with or without vaginal brachytherapy (VB).
  • One patient received whole-abdomen radiation therapy, and 13, adjuvant chemotherapy.
  • Solitary SI patients received pelvic RT with or without VB as their sole adjuvant therapy.
  • Factors correlated with disease recurrence included tumor stage (P = 0.003) and lymph node involvement (P = 0.04).
  • CONCLUSION: Endometrial carcinoma patients with SI have a high rate of relapse and a poor outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11531290.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5 T32 GM07281
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement